CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Claudin18.2-targeted cancer theranostics.
Claudin18.2-targeted cancer theranostics.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
Claudin 18.2（CLDN18.2）是治疗表达该靶点癌症的新兴靶点，包括胃癌和胰腺癌。靶向CLDN18.2的细胞疗法和抗体疗法正在多项临床试验中积极评估。在这一背景下，如何在治疗前后高效且特异地检测CLDN18.2表达，是一项临床挑战。近年来，采用放射性标记抗体或抗体片段进行分子影像，已显示出非侵入性描绘全身抗原表达的潜力。本文介绍CLDN18.2靶向实体瘤影像和治疗的最新进展。
Claudin 18. 2 (CLDN18. 2) is an emerging target for the treatment of CLDN18. 2-expressing cancers such as gastric and pancreatic cancers. Cell and antibody therapies targeting CLDN18. 2 are under intensive clinical trials. In this setting, how to efficiently and specifically detect CLDN18. 2 expression before and after the therapies is a clinical challenge.
In recent years, molecular imaging with radiolabeled antibodies or antibody fragments have shown promise in noninvasively annotating antigen expression across the body. In this Perspective , we will bring together the most recent progress on CLDN18. 2-targeted imaging and therapy of solid tumors.
在 PubMed 查看 → 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
